Silence Therapeutics plc
SLNCF
$0.95
$0.451490.53%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1,180.55% | -58.05% | -93.38% | 13.90% | -64.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,180.55% | -58.05% | -93.38% | 13.90% | -64.35% |
| Cost of Revenue | 57.35% | 77.41% | -6.09% | -49.03% | -68.25% |
| Gross Profit | 4,086.30% | -240.83% | -132.77% | 55.62% | -47.73% |
| SG&A Expenses | 30.94% | 16.13% | 4.19% | -16.30% | 27.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 129.36% | 57.04% | -7.26% | -26.47% | -55.68% |
| Operating Income | 209.44% | -82.40% | -61.18% | 64.28% | 51.92% |
| Income Before Tax | 334.35% | -190.74% | -46.35% | 72.27% | 53.31% |
| Income Tax Expenses | -2.40% | -34.11% | -17.70% | 37.02% | 710.04% |
| Earnings from Continuing Operations | 159.17% | -236.52% | -50.79% | 80.80% | -8.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 159.17% | -236.52% | -50.79% | 80.80% | -8.10% |
| EBIT | 209.44% | -82.40% | -61.18% | 64.28% | 51.92% |
| EBITDA | 214.46% | -83.28% | -61.80% | 64.92% | 52.67% |
| EPS Basic | 148.75% | -166.71% | -16.67% | 84.29% | 0.09% |
| Normalized Basic EPS | 293.13% | -130.47% | -13.24% | 77.29% | 56.85% |
| EPS Diluted | 148.75% | -166.71% | -16.67% | 84.29% | 0.09% |
| Normalized Diluted EPS | 293.13% | -130.47% | -13.24% | 77.29% | 56.85% |
| Average Basic Shares Outstanding | 21.34% | 26.16% | 29.24% | 22.18% | 8.20% |
| Average Diluted Shares Outstanding | 21.34% | 26.16% | 29.24% | 22.18% | 8.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |